Thalidomide naast dexamethason geeft bij Kahler - Multiple Myeloma een significant positief effect op aanslaan van behandeling, aldus Fase III studie.

15 juni 2004: Bron: International Myeloma Foundation

Een fase III studie bij Kahler - Multiple Myeloma patiënten toonde aan dat nieuw gediagnosteerde patiënten beter af zijn met de oraal in te nemen medicijnencombinatie Thalidomide en dexamethason dan alleen met dexamethason. Gemeten naar het eiwitgehalte - serum paraprotein concentrations - bij de patiënten bleek de groep van de combinatietherapie Thalidomide en dexamethason in 68% van de gevallen ontvankelijk voor deze therapie tegenover 46% in de dexamethasongroep. Na vier maanden bleek in de combinatiegroep 59% te reageren tegenover 41% in de dexamethasongroep. In dit persbericht wordt verder geen melding gemaakt van verschil in overlevingstijd en verschil in bijwerkingen. Lees ook ervaringsverhaal van Jan die al 17 jaar leeft met uitstekende kwaliteit van leven met Kahler - Multiple Myeloma. Of lees verhaal van meneer HA die met deze combinatie aanpak van o.a. thaliomide en extra goede voeding en suppletie ook zijn Kahler onder controle houdt. Of lees positieve ervaringsverhalen van Loes en Antoon met hun aanvullende aanpak met dieet en extra voedingssupplementen van de ziekte van Waldenström een aan Kahler - Multiple Meyloma verwante kankersoort.

NEW ORLEANS, June 7 /PRNewswire/ -- The International Myeloma Foundation (IMF), has commended the Eastern Cooperative Oncology Group (ECOG) report discussing the clinical benefits from a Phase III study (E1A00) using thalidomide plus dexamethasone as therapy in multiple myeloma. The clinical data was presented yesterday, June 6, at the American Society of Clinical Oncology (ASCO) conference. According to the findings presented, results of the study indicate patients newly diagnosed with multiple myeloma, an incurable cancer of the bone marrow, responded significantly better to treatment with the oral drug combination of thalidomide plus dexamenthasone (thal/dex). "This is a pivotal study that can clearly show the impact of thalidomide in a front line setting," stated Brian G.M. Durie, M.D., Chairman of the International Myeloma Foundation, and National Director for Hematologic Research and Myeloma Programs Salick Research Network and Los Angeles' Cedars Sinai Comprehensive Cancer Center. "Reviewing thalidomide's overall potential, the results of the study indicate an important step in regulatory approval with agencies such as the Federal Drug Administration," said Dr. Durie. In the just completed study, headed by S. Vincent Rajkumar, M.D., hematologist and associate professor of medicine at Mayo Clinic in Rochester, MN, there was a notable statistical difference of 59 percent versus 41 percent in response rates at 4 months with thalidomide plus dexamethasone compared to dexamethasone alone. When the data were analyzed for "Best Response" in reduction in serum paraprotein concentrations, 68% responded to the thalidomide/dexamethasone arm and 46% to the dexamethasone only arm. According to Susie Novis, President of the International Myeloma Foundation, "Patients will be offered a new therapy providing a better a quality of life during and after their treatment regime. The IMF commends the researchers and patients involved in the study. This is urgent news for us to disseminate immediately to the IMF membership." The International Myeloma Foundation (IMF) was founded in 1990 and is a 501(c)(3) non-profit corporation. The IMF is dedicated to finding a cure for multiple myeloma, also known as plasma cell neoplasm. The IMF is governed by a Board of Directors and guided by a Scientific Advisory Board. With a positive and expansive outreach to 120,000 members in over 100 countries, the IMF conducts educational patient seminars, clinical conferences, and scientific workshops; funds grant and scholarship programs; and offers patient and family support, advocacy and educational initiatives.

Plaats een reactie ...

Reageer op "Thalidomide naast dexamethason geeft bij Kahler - Multiple Myeloma een significant positief effect op aanslaan van behandeling, aldus Fase III studie. Artikel geplaatst juni 2004"

Gerelateerde artikelen

Gerelateerde artikelen

Thalidomide geeft bij Kahler >> Thalidomide remt hoog significant >> Reguliere oncologie: Kahler >>